Patient-based drug discovery's latest news

Link to photo source (UN) At Ksilink, it is one of our core missions to develop new therapeutic modalities to treat autism and particularly a rare form called Phelan McDermid...

Schumann G, Andreassen OA, Banaschewski T, et al. Addressing Global Environmental Challenges to Mental Health Using Population Neuroscience: A Review. JAMA Psychiatry....

Ksilink will be part of the 36th ECNP Congress in Barcelona, from October 7th to 10th 2023. Meet Karen Schmitt at the poster P.0070 during the poster session on 08/10/23, 12:35 -...

We are recruiting participants for a consensus conference about research on the link between the environment and #mentalhealth as part of the environMENTAL EU Project. Are you...

Our PhD student Vivien Batoumeni had the pleasure and honor to be awarded with the "Young Investigators" prize at Printemps de la cardiologie congress organized by Réseau Avenir...

We are very proud to contribute with our expertise in phenotypic and functional profiling of cardiac muscle disorders as a partner of another European consortium of excellence....

Discover how Ksilink, myriamed and their spin-off Myrtil Biotechnologies implement deep learning to enhance high-content screening and deep-tissue phenotyping to identify...

We will participate at this year’s Keystone Symposium on Modern Phenotypic Drug Discovery: From Chemical Biology to Therapy that will take place from May 22nd – May 25th 2022 in...

Ksilink proudly takes part of the EC funded EnvironMENTAL consortium. Want to know more? You are invited to join a series of seminars! EnvironMENTAL aims at identifying the...